ClinicalTrials.gg
CompletedNCT00344305Updated Jul 24, 2017Results posted

A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children

A Phase 2 interventional study of Trivalent influenza virus vaccine live, intranasal in Healthy, sponsored by MedImmune LLC. Completed at 16 sites in United States. Open to participants aged 6 Months to 59 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-24.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
6 Months to 59 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 37 studies testing FluMist in Influenza, Human — 4 open to participants now, 7 under way, none of them phase 3. FluMist · Influenza, Human.

Enrollment
13th of 37
200 · median 72
Started
2006
with 1 other
Phase 2
Only one
of the 37
Registered
11th of 37
by date
Lead sponsor
8 of 37
MedImmune LLC

Among the 37 studies testing FluMist in Influenza, Human, this one is the 13th largest by enrollment, is one of 2 that started in 2006, is the only one in phase 2, and was the 11th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

4 of the 37 studies testing FluMist in Influenza, Human are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About FluMist

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 6 Months to 59 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing FluMist in Influenza, Human, or all of them as a file.
02

Study summary

Open label, single arm, multicenter study of the shedding and safety of a single dose of trivalent, influenza virus vaccine live, intranasal in children 6 to \< 60 months of age, with 28-day shedding follow-up and 180-day safety follow-up.

Read the detailed description

This was a Phase 2, open-label, single-arm, multicenter study designed to evaluate vaccine virus shedding and safety of trivalent influenza virus vaccine live, intranasal in children 6 to \< 60 months of age. Enrollment of approximately 200 participants was stratified by age, with 100 participants 6 to \< 24 months of age (who reached their sixth month but not their second year birthday) and 100 participants 24 to \< 60 months of age (who reached their second year but not their fifth year birthday). Baseline medical history data collection included the participants prior receipt of influenza vaccine or history of laboratory-confirmed influenza illness in the previous influenza season.

03

Conditions studied

  • Healthy

Browse trials for

Keywords

  • children, FluMist, shedding,
04

Who can participate

Ages eligible
6 Months to 59 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 6 months to less than 60 months of age (reached their 6th month but not yet reached their 5th year birthday) at the time of study vaccination
  • Written and Health Insurance Portability and Accountability Act (HIPAA) authorization obtained from the participants parent/legal representative
  • Ability of the participants parent/legal representative to understand and comply with the requirements of the study
  • Participants parent/legal representative available by telephone
  • Ability to complete follow-up period of 180 days after study vaccination as required by the protocol

Exclusion criteria

Exclusion Criteria:

  • History of to any component of trivalent influenza virus vaccine live, intranasal, including egg or egg products, monosodium glutamate, or porcine gelatin
  • History of hypersensitivity to gentamicin
  • History of Guillain-Barré syndrome
  • Medically diagnosed wheezing, bronchodilator use, or use (systemic or inhaled), by parent/legal representative report or chart review, within the 42 days prior to study vaccination (i.e., children with recent persistent asthma were excluded); or history of severe persistent asthma according to the criteria described in the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report
  • Acute febrile (greater than or equal to [>=] 100.0 degree Fahrenheit [°F] oral or equivalent) and/or respiratory illness (e.g., cough or sore throat) within 72 hours prior to study vaccination
  • Any known condition or immune deficiency disease (including [HIV] infection), or ongoing receipt of any immunosuppressive therapy
  • Household contact who was immunocompromised (participants were also to avoid close contact with immunocompromised individuals for at least 21 days after study vaccination)
  • Use of aspirin or aspirin-containing products within the 30 days prior to study vaccination, or expected receipt through 180 days after study vaccination
  • Use of anti-influenza medications (including amantadine, rimantadine, oseltamivir, and zanamivir) within the 14 days prior to study vaccination, or expected receipt through 28 days after study vaccination
  • Use of any intranasal medication within the 14 days prior to study vaccination, or expected receipt through 28 days after study vaccination
  • Administration of any within the 30 days prior to study vaccination, or expected receipt through 30 days after study vaccination
  • Administration of any inactivated (i.e., non-live) vaccine within the 14 days prior to study vaccination, or expected receipt through 14 days after study vaccination
  • Receipt of any agent within the 30 days prior to study vaccination, or expected receipt through 180 days after study vaccination (use of licensed agents for indications not listed in the package insert was permitted)
  • Receipt of any blood product within the 90 days prior to study vaccination, or expected receipt through 28 days after study vaccination
  • Family member or household contact who was an employee of the research center or otherwise involved with the conduct of the study
  • Any condition that in the opinion of the investigator would have interfered with evaluation of the vaccine or interpretation of study results
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Cohort 1: Participants Between 6 to < 24 Months Age

    Participants received a single, intranasal dose of 0.2 millilitre (mL) (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10\^7 fluorescent focus units (FFU) of three influenza virus strains namely, A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2) (A/Fujian/411/2002-like) and B/Jilin/20/2003 (B/Shanghai/361/2002-like).

    Biological: Trivalent influenza virus vaccine live, intranasal

  • Experimental
    Cohort 2: Participants Between 24 to < 60 Months Age

    Participants received a single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10\^7 FFU of three influenza virus strains namely, A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2) (A/Fujian/411/2002-like) and B/Jilin/20/2003 (B/Shanghai/361/2002-like).

    Biological: Trivalent influenza virus vaccine live, intranasal

Interventions

  • A single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10\^7 FFU of three influenza virus strains.

    Also known as: FluMist, Cold-adapted influenza virus vaccine, trivalent (CAIV-T), Live attenuated influenza virus (LAIV)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Shed Any Vaccine Virus

    Viral shedding is defined as the detection of virus by viral culture and vaccine-type virus was confirmed by polymerase chain reaction (PCR) based assays. Viral shedding (A/New Caledonia/20/99 \[H1N1\]; A/Wyoming/03/2003 \[H3N2\] (A/Fujian/411/2002-like); B/Jilin/20/2003 B/Shanghai/361/2002-like\]) was measured from samples obtained from nasal swabs daily from Days 1 to 7 post vaccination and approximately every other day thereafter from Days 9 to 28. Participants whose Day 25 or 28 shedding sample was positive for vaccine virus had additional shedding samples collected approximately every 7 days, or as soon as possible upon awareness of culture positivity, until 2 consecutive samples were negative for vaccine virus.

    Time frame: Days 1-28 after study vaccination (up to Day 28)

  2. Percentage of Participants Who Shed A/H1N1 Vaccine Virus

    Viral shedding is defined as the detection of virus by viral culture and vaccine-type virus was confirmed by PCR based assays. Viral shedding (A/New Caledonia/20/99 \[H1N1\]; A/Wyoming/03/2003 \[H3N2\] (A/Fujian/411/2002-like); B/Jilin/20/2003 B/Shanghai/361/2002-like\]) was measured from samples obtained from nasal swabs daily from Days 1 to 7 post vaccination and approximately every other day thereafter from Days 9 to 28. Participants whose Day 25 or 28 shedding sample was positive for vaccine virus had additional shedding samples collected approximately every 7 days, or as soon as possible upon awareness of culture positivity, until 2 consecutive samples were negative for vaccine virus.

    Time frame: Days 1-28 after study vaccination (up to Day 28)

  3. Percentage of Participants Who Shed A/H3N2 Vaccine Virus

    Viral shedding is defined as the detection of virus by viral culture and vaccine-type virus was confirmed by PCR based assays. Viral shedding (A/New Caledonia/20/99 \[H1N1\]; A/Wyoming/03/2003 \[H3N2\] (A/Fujian/411/2002-like); B/Jilin/20/2003 B/Shanghai/361/2002-like\]) was measured from samples obtained from nasal swabs daily from Days 1 to 7 post vaccination and approximately every other day thereafter from Days 9 to 28. Participants whose Day 25 or 28 shedding sample was positive for vaccine virus had additional shedding samples collected approximately every 7 days, or as soon as possible upon awareness of culture positivity, until 2 consecutive samples were negative for vaccine virus.

    Time frame: Days 1-28 after study vaccination (up to Day 28)

  4. Percentage of Participants Who Shed B Vaccine Virus

    Viral shedding is defined as the detection of virus by viral culture and vaccine-type virus was confirmed by PCR based assays. Viral shedding (A/New Caledonia/20/99 \[H1N1\]; A/Wyoming/03/2003 \[H3N2\] (A/Fujian/411/2002-like); B/Jilin/20/2003 B/Shanghai/361/2002-like\]) was measured from samples obtained from nasal swabs daily from Days 1 to 7 post vaccination and approximately every other day thereafter from Days 9 to 28. Participants whose Day 25 or 28 shedding sample was positive for vaccine virus had additional shedding samples collected approximately every 7 days, or as soon as possible upon awareness of culture positivity, until 2 consecutive samples were negative for vaccine virus.

    Time frame: Days 1-28 after study vaccination (up to Day 28)

Secondary outcomes

  1. Duration of Any Vaccine Virus Shedding

    The number of days of shedding was summarized for all participants who shed any vaccine virus.

    Time frame: Days 1-28 after study vaccination (up to Day 28)

  2. Duration of Confirmed A/H1N1 Vaccine Virus Shedding

    The number of days of shedding was summarized for all participants who shed confirmed A/H1N1 strain virus.

    Time frame: Days 1-28 after study vaccination (up to Day 28)

  3. Duration of Confirmed A/H3N2 Vaccine Virus Shedding

    The number of days of shedding was summarized for all participants who shed confirmed A/H3N2 strain virus.

    Time frame: Days 1-28 after study vaccination (up to Day 28)

  4. Duration of Confirmed B Vaccine Virus Shedding

    The number of days of shedding was summarized for all participants who shed confirmed B strain virus.

    Time frame: Days 1-28 after study vaccination (up to Day 28)

  5. Quantitation of Confirmed A/H1N1 Shed Vaccine Virus on Any Day

    Quantitation of confirmed A/H1N1 shed vaccine virus was evaluated using the log transformed median tissue culture infectious dose (TCID50) per (/) millilitre (mL) for A/H1N1 vaccine strain and summarized for all participants who shed vaccine virus.

    Time frame: Days 1-28 after study vaccination (up to Day 28)

  6. Quantitation of Confirmed A/H3N2 Shed Vaccine Virus on Any Day

    Quantitation of confirmed A/H3N2 shed vaccine virus was evaluated using the log (TCID50)/mL for A/H3N2 vaccine strain and summarized for all participants who shed vaccine virus.

    Time frame: Days 1-28 after study vaccination (up to Day 28)

  7. Quantitation of Confirmed B Shed Vaccine Virus on Any Day

    Quantitation of confirmed B shed vaccine virus was evaluated using the log (TCID50)/mL for B vaccine strain and summarized for all participants who shed vaccine virus.

    Time frame: Days 1-28 after study vaccination (up to Day 28)

  8. Number of Participants With Genotypic and Phenotypic Stability of A/H1N1 Shed Vaccine Virus

    The genetic and phenotypic stability of shed vaccine virus was evaluated by determination of genomic sequence and assessment of the cold-adapted (ca) and temperature-sensitive (ts) phenotypes. Viruses were considered ts if their titer at 39 degrees Celsius (°C) was at least two logs (100-fold) lower than their titer at 33°C. Viruses were considered ca if they replicated at 25°C to a titer that was no more than two logs (100-fold) lower than the titer at 33°C. After additional phenotypic and genotypic analyses, all evaluable samples retained the ca and ts phenotypes.

    Time frame: Days 1-28 after study vaccination (up to Day 28)

  9. Number of Participants With Genotypic and Phenotypic Stability of A/H3N2 Shed Vaccine Virus

    The genetic and phenotypic stability of shed vaccine virus was evaluated by determination of genomic sequence and assessment of the ca and ts phenotypes. Viruses were considered ts if their titer at 39°C was at least two logs (100-fold) lower than their titer at 33°C. Viruses were considered ca if they replicated at 25°C to a titer that was no more than two logs (100-fold) lower than the titer at 33°C. After additional phenotypic and genotypic analyses, all evaluable samples retained the ca and ts phenotypes.

    Time frame: Days 1-28 after study vaccination (up to Day 28)

  10. Number of Participants With Genotypic and Phenotypic Stability of B Shed Vaccine Virus

    The genetic and phenotypic stability of shed vaccine virus was evaluated by determination of genomic sequence and assessment of the ca and ts phenotypes. Viruses were considered ts if their titer at 37°C was at least two logs (100-fold) lower than their titer at 33°C. Viruses were considered ca if they replicated at 25°C to a titer that was no more than two logs (100-fold) lower than the titer at 33°C. After additional phenotypic and genotypic analyses, all evaluable samples retained the ca and ts phenotypes.

    Time frame: Days 1-28 after study vaccination (up to Day 28)

  11. Number of Participants With Reactogenicity Events (REs) and Adverse Events (AEs) Through 28 Days Post Vaccination

    REs were predefined solicited events that could potentially occur after vaccination. The REs for this study were fever, runny/stuffy nose, sore throat, cough, vomiting, headache, abdominal pain (stomach ache), muscle ache, chills, decreased activity level (lethargy), decreased appetite, and irritability. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

    Time frame: Days 0-28 after vaccination (up to Day 28)

  12. Number of Participants With Serious Adverse Events (SAEs) and Significant New Medical Conditions (SNMC) Through 180 Days Post Vaccination

    An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. An SNMC is defined as a newly diagnosed medical condition that was of a chronic, ongoing nature and was assessed by the investigator as medically significant. SNMCs included, but were not limited to, diabetes, asthma, autoimmune disease (lupus, rheumatoid arthritis), and neurological disease (epilepsy, autism).

    Time frame: Days 0-180 after vaccination (up to 6.5 months)

  13. Number of Participants With REs in Relation to Any Vaccine Virus Shedding

    REs were predefined solicited events that could potentially occur after vaccination. The REs for this study were fever, runny/stuffy nose, sore throat, cough, vomiting, headache, abdominal pain (stomach ache), muscle ache, chills, decreased activity level (lethargy), decreased appetite, and irritability.

    Time frame: Days 0-28 after study vaccination (up to Day 28)

07

Results

Posted Nov 1, 2010

Participant flow

A total of 200 participants were enrolled in the study from 15-May-2006 through 22-Jun-2006 at 16 sites in the United States of America.

Participant flow — Overall Study
MilestoneCohort 1: Participants Between 6 to < 24 Months AgeCohort 2: Participants Between 24 to < 60 Months Age
Started100100
Completed9899
Not completed21
Withdrew: Lost to follow-up20
Withdrew: Participant was not contacted in window01

Outcome measures

PrimaryPercentage of Participants Who Shed Any Vaccine Virus

Viral shedding is defined as the detection of virus by viral culture and vaccine-type virus was confirmed by polymerase chain reaction (PCR) based assays. Viral shedding (A/New Caledonia/20/99 \[H1N1\]; A/Wyoming/03/2003 \[H3N2\] (A/Fujian/411/2002-like); B/Jilin/20/2003 B/Shanghai/361/2002-like\]) was measured from samples obtained from nasal swabs daily from Days 1 to 7 post vaccination and approximately every other day thereafter from Days 9 to 28. Participants whose Day 25 or 28 shedding sample was positive for vaccine virus had additional shedding samples collected approximately every 7 days, or as soon as possible upon awareness of culture positivity, until 2 consecutive samples were negative for vaccine virus.

Time frame:
Days 1-28 after study vaccination (up to Day 28)
Reported as:
Number · percentage of participants
Percentage of Participants Who Shed Any Vaccine Virus
percentage of participantsCohort 1: Participants Between 6 to < 24 Months AgeCohort 2: Participants Between 24 to < 60 Months Age
Percentage of Participants Who Shed Any Vaccine Virus88.9 (81.0 to 94.3)69.0 (59.0 to 77.9)
PrimaryPercentage of Participants Who Shed A/H1N1 Vaccine Virus

Viral shedding is defined as the detection of virus by viral culture and vaccine-type virus was confirmed by PCR based assays. Viral shedding (A/New Caledonia/20/99 \[H1N1\]; A/Wyoming/03/2003 \[H3N2\] (A/Fujian/411/2002-like); B/Jilin/20/2003 B/Shanghai/361/2002-like\]) was measured from samples obtained from nasal swabs daily from Days 1 to 7 post vaccination and approximately every other day thereafter from Days 9 to 28. Participants whose Day 25 or 28 shedding sample was positive for vaccine virus had additional shedding samples collected approximately every 7 days, or as soon as possible upon awareness of culture positivity, until 2 consecutive samples were negative for vaccine virus.

Time frame:
Days 1-28 after study vaccination (up to Day 28)
Reported as:
Number · percentage of participants
Percentage of Participants Who Shed A/H1N1 Vaccine Virus
percentage of participantsCohort 1: Participants Between 6 to < 24 Months AgeCohort 2: Participants Between 24 to < 60 Months Age
Percentage of Participants Who Shed A/H1N1 Vaccine Virus76.8 (67.2 to 84.7)52.0 (41.8 to 62.1)
PrimaryPercentage of Participants Who Shed A/H3N2 Vaccine Virus

Viral shedding is defined as the detection of virus by viral culture and vaccine-type virus was confirmed by PCR based assays. Viral shedding (A/New Caledonia/20/99 \[H1N1\]; A/Wyoming/03/2003 \[H3N2\] (A/Fujian/411/2002-like); B/Jilin/20/2003 B/Shanghai/361/2002-like\]) was measured from samples obtained from nasal swabs daily from Days 1 to 7 post vaccination and approximately every other day thereafter from Days 9 to 28. Participants whose Day 25 or 28 shedding sample was positive for vaccine virus had additional shedding samples collected approximately every 7 days, or as soon as possible upon awareness of culture positivity, until 2 consecutive samples were negative for vaccine virus.

Time frame:
Days 1-28 after study vaccination (up to Day 28)
Reported as:
Number · percentage of participants
Percentage of Participants Who Shed A/H3N2 Vaccine Virus
percentage of participantsCohort 1: Participants Between 6 to < 24 Months AgeCohort 2: Participants Between 24 to < 60 Months Age
Percentage of Participants Who Shed A/H3N2 Vaccine Virus57.6 (47.2 to 67.5)15.0 (8.6 to 23.5)
PrimaryPercentage of Participants Who Shed B Vaccine Virus

Viral shedding is defined as the detection of virus by viral culture and vaccine-type virus was confirmed by PCR based assays. Viral shedding (A/New Caledonia/20/99 \[H1N1\]; A/Wyoming/03/2003 \[H3N2\] (A/Fujian/411/2002-like); B/Jilin/20/2003 B/Shanghai/361/2002-like\]) was measured from samples obtained from nasal swabs daily from Days 1 to 7 post vaccination and approximately every other day thereafter from Days 9 to 28. Participants whose Day 25 or 28 shedding sample was positive for vaccine virus had additional shedding samples collected approximately every 7 days, or as soon as possible upon awareness of culture positivity, until 2 consecutive samples were negative for vaccine virus.

Time frame:
Days 1-28 after study vaccination (up to Day 28)
Reported as:
Number · percentage of participants
Percentage of Participants Who Shed B Vaccine Virus
percentage of participantsCohort 1: Participants Between 6 to < 24 Months AgeCohort 2: Participants Between 24 to < 60 Months Age
Percentage of Participants Who Shed B Vaccine Virus37.4 (27.9 to 47.7)37.0 (27.6 to 47.2)
SecondaryDuration of Any Vaccine Virus Shedding

The number of days of shedding was summarized for all participants who shed any vaccine virus.

Time frame:
Days 1-28 after study vaccination (up to Day 28)
Reported as:
Mean · days
Duration of Any Vaccine Virus Shedding
daysCohort 1: Participants Between 6 to < 24 Months AgeCohort 2: Participants Between 24 to < 60 Months Age
Duration of Any Vaccine Virus Shedding3.0 ± 1.52.7 ± 1.6
SecondaryDuration of Confirmed A/H1N1 Vaccine Virus Shedding

The number of days of shedding was summarized for all participants who shed confirmed A/H1N1 strain virus.

Time frame:
Days 1-28 after study vaccination (up to Day 28)
Reported as:
Mean · days
Duration of Confirmed A/H1N1 Vaccine Virus Shedding
daysCohort 1: Participants Between 6 to < 24 Months AgeCohort 2: Participants Between 24 to < 60 Months Age
Duration of Confirmed A/H1N1 Vaccine Virus Shedding2.1 ± 1.02.2 ± 1.3
SecondaryDuration of Confirmed A/H3N2 Vaccine Virus Shedding

The number of days of shedding was summarized for all participants who shed confirmed A/H3N2 strain virus.

Time frame:
Days 1-28 after study vaccination (up to Day 28)
Reported as:
Mean · days
Duration of Confirmed A/H3N2 Vaccine Virus Shedding
daysCohort 1: Participants Between 6 to < 24 Months AgeCohort 2: Participants Between 24 to < 60 Months Age
Duration of Confirmed A/H3N2 Vaccine Virus Shedding1.8 ± 0.91.7 ± 0.8
SecondaryDuration of Confirmed B Vaccine Virus Shedding

The number of days of shedding was summarized for all participants who shed confirmed B strain virus.

Time frame:
Days 1-28 after study vaccination (up to Day 28)
Reported as:
Mean · days
Duration of Confirmed B Vaccine Virus Shedding
daysCohort 1: Participants Between 6 to < 24 Months AgeCohort 2: Participants Between 24 to < 60 Months Age
Duration of Confirmed B Vaccine Virus Shedding2.1 ± 1.51.8 ± 1.2
SecondaryQuantitation of Confirmed A/H1N1 Shed Vaccine Virus on Any Day

Quantitation of confirmed A/H1N1 shed vaccine virus was evaluated using the log transformed median tissue culture infectious dose (TCID50) per (/) millilitre (mL) for A/H1N1 vaccine strain and summarized for all participants who shed vaccine virus.

Time frame:
Days 1-28 after study vaccination (up to Day 28)
Reported as:
Mean · log (TCID50)/mL
Quantitation of Confirmed A/H1N1 Shed Vaccine Virus on Any Day
log (TCID50)/mLCohort 1: Participants Between 6 to < 24 Months AgeCohort 2: Participants Between 24 to < 60 Months Age
Quantitation of Confirmed A/H1N1 Shed Vaccine Virus on Any Day2.14 ± 0.982.62 ± 0.97
SecondaryQuantitation of Confirmed A/H3N2 Shed Vaccine Virus on Any Day

Quantitation of confirmed A/H3N2 shed vaccine virus was evaluated using the log (TCID50)/mL for A/H3N2 vaccine strain and summarized for all participants who shed vaccine virus.

Time frame:
Days 1-28 after study vaccination (up to Day 28)
Reported as:
Mean · log (TCID50)/mL
Quantitation of Confirmed A/H3N2 Shed Vaccine Virus on Any Day
log (TCID50)/mLCohort 1: Participants Between 6 to < 24 Months AgeCohort 2: Participants Between 24 to < 60 Months Age
Quantitation of Confirmed A/H3N2 Shed Vaccine Virus on Any Day1.59 ± 0.951.10 ± 0.53
SecondaryQuantitation of Confirmed B Shed Vaccine Virus on Any Day

Quantitation of confirmed B shed vaccine virus was evaluated using the log (TCID50)/mL for B vaccine strain and summarized for all participants who shed vaccine virus.

Time frame:
Days 1-28 after study vaccination (up to Day 28)
Reported as:
Mean · log (TCID50)/mL
Quantitation of Confirmed B Shed Vaccine Virus on Any Day
log (TCID50)/mLCohort 1: Participants Between 6 to < 24 Months AgeCohort 2: Participants Between 24 to < 60 Months Age
Quantitation of Confirmed B Shed Vaccine Virus on Any Day1.70 ± 1.091.24 ± 0.68
SecondaryNumber of Participants With Genotypic and Phenotypic Stability of A/H1N1 Shed Vaccine Virus

The genetic and phenotypic stability of shed vaccine virus was evaluated by determination of genomic sequence and assessment of the cold-adapted (ca) and temperature-sensitive (ts) phenotypes. Viruses were considered ts if their titer at 39 degrees Celsius (°C) was at least two logs (100-fold) lower than their titer at 33°C. Viruses were considered ca if they replicated at 25°C to a titer that was no more than two logs (100-fold) lower than the titer at 33°C. After additional phenotypic and genotypic analyses, all evaluable samples retained the ca and ts phenotypes.

Time frame:
Days 1-28 after study vaccination (up to Day 28)
Reported as:
Number · participants
Number of Participants With Genotypic and Phenotypic Stability of A/H1N1 Shed Vaccine Virus
participantsAll Participants
Genotypic Stability (n=0)NA
Phenotypic Stability (n=93)90
SecondaryNumber of Participants With Genotypic and Phenotypic Stability of A/H3N2 Shed Vaccine Virus

The genetic and phenotypic stability of shed vaccine virus was evaluated by determination of genomic sequence and assessment of the ca and ts phenotypes. Viruses were considered ts if their titer at 39°C was at least two logs (100-fold) lower than their titer at 33°C. Viruses were considered ca if they replicated at 25°C to a titer that was no more than two logs (100-fold) lower than the titer at 33°C. After additional phenotypic and genotypic analyses, all evaluable samples retained the ca and ts phenotypes.

Time frame:
Days 1-28 after study vaccination (up to Day 28)
Reported as:
Number · participants
Number of Participants With Genotypic and Phenotypic Stability of A/H3N2 Shed Vaccine Virus
participantsAll Participants
Genotypic Stability (n=0)NA
Phenotypic Stability (n=39)37
SecondaryNumber of Participants With Genotypic and Phenotypic Stability of B Shed Vaccine Virus

The genetic and phenotypic stability of shed vaccine virus was evaluated by determination of genomic sequence and assessment of the ca and ts phenotypes. Viruses were considered ts if their titer at 37°C was at least two logs (100-fold) lower than their titer at 33°C. Viruses were considered ca if they replicated at 25°C to a titer that was no more than two logs (100-fold) lower than the titer at 33°C. After additional phenotypic and genotypic analyses, all evaluable samples retained the ca and ts phenotypes.

Time frame:
Days 1-28 after study vaccination (up to Day 28)
Reported as:
Number · participants
Number of Participants With Genotypic and Phenotypic Stability of B Shed Vaccine Virus
participantsAll Participants
Genotypic Stability (n=33)33
Phenotypic Stability (n=61)29
SecondaryNumber of Participants With Reactogenicity Events (REs) and Adverse Events (AEs) Through 28 Days Post Vaccination

REs were predefined solicited events that could potentially occur after vaccination. The REs for this study were fever, runny/stuffy nose, sore throat, cough, vomiting, headache, abdominal pain (stomach ache), muscle ache, chills, decreased activity level (lethargy), decreased appetite, and irritability. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

Time frame:
Days 0-28 after vaccination (up to Day 28)
Reported as:
Number · participants
Number of Participants With Reactogenicity Events (REs) and Adverse Events (AEs) Through 28 Days Post Vaccination
participantsCohort 1: Participants Between 6 to < 24 Months AgeCohort 2: Participants Between 24 to < 60 Months Age
Any REs8477
AEs4831
SecondaryNumber of Participants With Serious Adverse Events (SAEs) and Significant New Medical Conditions (SNMC) Through 180 Days Post Vaccination

An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. An SNMC is defined as a newly diagnosed medical condition that was of a chronic, ongoing nature and was assessed by the investigator as medically significant. SNMCs included, but were not limited to, diabetes, asthma, autoimmune disease (lupus, rheumatoid arthritis), and neurological disease (epilepsy, autism).

Time frame:
Days 0-180 after vaccination (up to 6.5 months)
Reported as:
Number · participants
Number of Participants With Serious Adverse Events (SAEs) and Significant New Medical Conditions (SNMC) Through 180 Days Post Vaccination
participantsCohort 1: Participants Between 6 to < 24 Months AgeCohort 2: Participants Between 24 to < 60 Months Age
SAEs10
SNMC11
SecondaryNumber of Participants With REs in Relation to Any Vaccine Virus Shedding

REs were predefined solicited events that could potentially occur after vaccination. The REs for this study were fever, runny/stuffy nose, sore throat, cough, vomiting, headache, abdominal pain (stomach ache), muscle ache, chills, decreased activity level (lethargy), decreased appetite, and irritability.

Time frame:
Days 0-28 after study vaccination (up to Day 28)
Reported as:
Number · participants
Number of Participants With REs in Relation to Any Vaccine Virus Shedding
participantsCohort 1: Participants Between 6 to < 24 Months AgeCohort 2: Participants Between 24 to < 60 Months Age
Number of Participants With REs in Relation to Any Vaccine Virus Shedding7555

Adverse events

Collected over AEs - Days 0-28 post dosing (up to Day 28); SAEs - Days 0-180 post dosing (up to 6.5 months). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Participants Between 6 to < 24 Months Age—1/100 (1%)48/100 (48%)
Cohort 2: Participants Between 24 to < 60 Months Age—0/100 (0%)25/100 (25%)
Most frequent serious events
Most frequent serious events
EventCohort 1: Participants Between 6 to < 24 Months AgeCohort 2: Participants Between 24 to < 60 Months Age
AsthmaRespiratory, thoracic and mediastinal disorders1/1000/100
Most frequent other events
Showing 10 of 15
Most frequent other events
EventCohort 1: Participants Between 6 to < 24 Months AgeCohort 2: Participants Between 24 to < 60 Months Age
TEETHINGGastrointestinal disorders21/1000/100
DIARRHOEAGastrointestinal disorders5/1009/100
OTITIS MEDIAInfections and infestations4/1000/100
ARTHROPOD BITEInjury, poisoning and procedural complications4/1003/100
PHARYNGITIS STREPTOCOCCALInfections and infestations1/1003/100
VIRAL INFECTIONInfections and infestations3/1002/100
BODY TEMPERATURE INCREASEDInvestigations3/1002/100
EPISTAXISRespiratory, thoracic and mediastinal disorders3/1002/100
OTORRHOEAEar and labyrinth disorders2/1000/100
CONJUNCTIVITISEye disorders2/1000/100

Baseline characteristics

Age, Continuous
Age, Continuous(months)Cohort 1: Participants Between 6 to < 24 Months AgeCohort 2: Participants Between 24 to < 60 Months AgeTotal
Mean14.87 ± 5.5041.31 ± 9.9828.09 ± 15.50
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Participants Between 6 to < 24 Months AgeCohort 2: Participants Between 24 to < 60 Months AgeTotal
Female5153104
Male494796
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Participants Between 6 to < 24 Months AgeCohort 2: Participants Between 24 to < 60 Months AgeTotal
Hispanic or Latino71522
Not Hispanic or Latino9385178
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Participants Between 6 to < 24 Months AgeCohort 2: Participants Between 24 to < 60 Months AgeTotal
American Indian or Alaska Native011
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American14721
White8689175
More than one race011
Unknown or Not Reported000
History of laboratory-confirmed influenza illness in previous influenza season
History of laboratory-confirmed influenza illness in previous influenza season(participants)Cohort 1: Participants Between 6 to < 24 Months AgeCohort 2: Participants Between 24 to < 60 Months AgeTotal
Yes123
No9998197
History of receiving an influenza vaccine
History of receiving an influenza vaccine(participants)Cohort 1: Participants Between 6 to < 24 Months AgeCohort 2: Participants Between 24 to < 60 Months AgeTotal
Yes4373116
No572784
08

Study locations

16 sites
  • Little Rock Allergy & Asthma Clinic, PA
    Little Rock, Arkansas 72205, United States
  • Pediatric and Adolescent Medicine, PA (PAMPA)
    Marietta, Georgia 30062, United States
  • Kentucky Pediatrics/Adult Research
    Bardstown, Kentucky 40004, United States
  • Benchmark Research
    Metairie, Louisiana 70006, United States
  • Health Sciences Research Center
    Cortland, New York 13045, United States
  • Health Sciences Research Center
    Elmira, New York 14901, United States
  • Regional Clinical Research Inc.
    Endwell, New York 13760, United States
  • Grand Prairie Pediatrics & Allergy Clinic
    Oklahoma City, Oklahoma 73132, United States
  • Primary Physicians Research , Inc
    Pittsburgh, Pennsylvania 15241, United States
  • Med-Pro Research Inc.
    Houston, Texas 77004, United States
  • Central Texas Health Research
    New Braunfels, Texas 78130, United States
  • Benchmark Research
    San Angelo, Texas 76904, United States
  • Wee Care Pediatrics
    Layton, Utah 84041, United States
  • Utah Valley Pediatrics
    Provo, Utah 84604, United States
  • PI-Coor Clinical Research, LLC
    Burke, Virginia 22015, United States
  • Advanced Pediatrics
    Vienna, Virginia 22180, United States
09

References and documents

Publications

  • Mallory RM, Yi T, Ambrose CS. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age. Vaccine. 2011 Jun 10;29(26):4322-7. doi: 10.1016/j.vaccine.2011.04.022. Epub 2011 Apr 20. PubMed 21513761 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2006 to primary completion in Jul 2006, 2 months.

Results were first posted in Nov 2010, 4 years 4 months after primary completion.

Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 2 months is below that.

Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2006
First posted
Jun 26, 2006
StartActual
May 1, 2006
Primary completionActual
Jul 1, 2006
CompletionActual
Dec 1, 2006
Results first posted
Nov 1, 2010
Last update
Jul 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00344305
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Jun 26, 2006
Start date
May 1, 2006
Primary completion
Jul 1, 2006
Completion
Dec 1, 2006
Results posted
Nov 1, 2010
Last update
Jul 24, 2017

Study contacts

Raburn Mallory, M.D.
study director · MedImmune LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FluMist

Start the discussion